HSBC Holdings
CRBP icon

HSBC Holdings’s Corbus Pharmaceuticals CRBP Stock Holding History

HSBC Holdings’s Portfolio CRBP Stock Details CRBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,357
Closed -$198K – 3062
2019
Q3 		$198K Buy
+1,357
New +$236K ﹤0.01% 2871
2017
Q2 		– Sell
-1,162
Closed -$288K – 2195
2017
Q1 		$288K Buy
+1,162
New +$285K ﹤0.01% 1821

Other funds holding CRBP

EMG
ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Knoll Capital Management Miami, Florida $180M AUM 66.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

HSBC Holdings's CRBP Position: Q4 2019 in Review

HSBC Holdings sold out of Corbus Pharmaceuticals (CRBP) in Q4 2019, closing a stake of 1,357 shares — an estimated $198K sold.

HSBC Holdings first reported a position in CRBP in Q1 2017 and held it in 2 quarters. The position peaked at $288K in Q1 2017. 105 funds tracked by Wall St. Rank hold CRBP as of Q4 2019.

  • HSBC Holdings reported no remaining Corbus Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • HSBC Holdings sold 1,357 Corbus Pharmaceuticals shares in Q4 2019, an estimated $198K.
  • HSBC Holdings first reported a position in Corbus Pharmaceuticals in Q1 2017 and held it in 2 quarters.
  • HSBC Holdings's Corbus Pharmaceuticals position peaked at $288K in Q1 2017.
  • 105 funds tracked by Wall St. Rank held Corbus Pharmaceuticals as of Q4 2019.

Based on HSBC Holdings's 13F filing for Q4 2019, filed 14 Feb 2020.